drugset / Trial / NCT02895815

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

NCT02895815 ↗

Phase 2 Withdrawn Janssen Pharmaceutical K.K.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD).

Timeline

Start
2018-04-09
Primary completion
2021-02-20
Completion
2022-08-19

Outcome

Outcome not reported

Stopped (Business): “Company business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTO 2476 Cell therapy 60000 cells Other
Subject CNTO 2476 Cell therapy 300000 cells Other